<DOC>
	<DOCNO>NCT00228150</DOCNO>
	<brief_summary>The primary objective ass effect SR57667B dose 4 mg/d progression Parkinson symptoms patient early PD . The primary outcome time progression disability warrant initiation L-dopa dopamine agonist . Secondary outcome comprise assessment symptom , activity daily live global clinical status .</brief_summary>
	<brief_title>Study Effect SR57667B Progression Symptoms Patients With Parkinson 's Disease</brief_title>
	<detailed_description>Multinational , multicenter , randomize , parallel-group , double-blind , phase II study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Male female outpatient . Age &gt; =35 year screening.· Diagnosis Parkinson 's syndrome , least two three key Parkinson 's symptom , i.e . rest tremor , bradykinesia rigidity . Duration disease less 3 year since diagnosis· Modified Hoehn Yahr stage &lt; = 2.5 . Untreated patient . Generally healthy ambulatory . Patient give inform write consent capable follow study procedure . Any indication form parkinsonism PD . Severe rest tremor . Presence either dyskinesia , fluctuation , loss postural reflexes· Treatment LDopa , dopamine agonist , amantadine , anticholinergic , catecholomethyltransferase ( COMT ) inhibitor , selegiline , dopamine receptor antagonist , catecholamine depleters , indirect dopamine agonist alphamethyldopa . Electroconvulsive therapy ( ECT ) . Use CYP3A4 strong , moderate inducer inhibitor . Participation another clinical trial investigational drug within two month prior randomization . Dementia , uncontrolled depression , psychotic disorder . History substancerelated disorder include alcohol substance use disorder . Females child bear potential . Evidence ( detected history , physical examination and/or laboratory/ECG test ) clinically significant unstable medical disorder could interfere patient 's participation clinical trial ; interfere absorption , metabolism excretion study medication ; interfere evaluation study drug . Alterations laboratory test ECG finding potential clinical significance .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>dopamine agonist</keyword>
</DOC>